MX2020011774A - Compuestos de naftiridina como inhibidores de quinasa jak. - Google Patents
Compuestos de naftiridina como inhibidores de quinasa jak.Info
- Publication number
- MX2020011774A MX2020011774A MX2020011774A MX2020011774A MX2020011774A MX 2020011774 A MX2020011774 A MX 2020011774A MX 2020011774 A MX2020011774 A MX 2020011774A MX 2020011774 A MX2020011774 A MX 2020011774A MX 2020011774 A MX2020011774 A MX 2020011774A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- kinase inhibitors
- jak kinase
- naphthyridine compounds
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona compuestos de la fórmula (I): (ver Fórmula) en donde las variables se definen en la especificación, o una sal farmacéuticamente aceptable del mismo, que son inhibidores de quinasas JAK. La invención también proporciona composiciones farmacéuticas que comprenden tales compuestos, métodos para usar tales compuestos para tratar enfermedades intestinales inflamatorias, y procesos e intermediarios útiles para preparar tales compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562167694P | 2015-05-28 | 2015-05-28 | |
| US201662312273P | 2016-03-23 | 2016-03-23 | |
| PCT/US2016/034243 WO2016191524A1 (en) | 2015-05-28 | 2016-05-26 | Naphthyridine compounds as jak kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011774A true MX2020011774A (es) | 2021-06-01 |
Family
ID=56118022
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011774A MX2020011774A (es) | 2015-05-28 | 2016-05-26 | Compuestos de naftiridina como inhibidores de quinasa jak. |
| MX2017015211A MX2017015211A (es) | 2015-05-28 | 2016-05-26 | Compuestos de naftiridina como inhibidores de quinasa jak. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017015211A MX2017015211A (es) | 2015-05-28 | 2016-05-26 | Compuestos de naftiridina como inhibidores de quinasa jak. |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US9725470B2 (es) |
| EP (2) | EP3569604B1 (es) |
| JP (4) | JP6692836B2 (es) |
| KR (1) | KR20180011272A (es) |
| CN (2) | CN107667108B (es) |
| AU (2) | AU2016267141B2 (es) |
| BR (1) | BR112017025542A2 (es) |
| CA (1) | CA2983453A1 (es) |
| CL (1) | CL2017002994A1 (es) |
| CO (1) | CO2017012267A2 (es) |
| CY (1) | CY1122279T1 (es) |
| DK (1) | DK3303348T3 (es) |
| EA (1) | EA032953B1 (es) |
| ES (2) | ES2924698T3 (es) |
| HK (1) | HK1245771A1 (es) |
| HU (1) | HUE046130T2 (es) |
| IL (3) | IL255358B (es) |
| LT (1) | LT3303348T (es) |
| ME (1) | ME03610B (es) |
| MX (2) | MX2020011774A (es) |
| PH (1) | PH12017502050A1 (es) |
| PL (1) | PL3303348T3 (es) |
| PT (1) | PT3303348T (es) |
| RS (1) | RS59522B1 (es) |
| SA (1) | SA517390337B1 (es) |
| SG (1) | SG10201910742VA (es) |
| SI (1) | SI3303348T1 (es) |
| TW (2) | TWI746178B (es) |
| UA (1) | UA121138C2 (es) |
| WO (1) | WO2016191524A1 (es) |
| ZA (1) | ZA201707326B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3303348T (lt) | 2015-05-28 | 2019-11-25 | Theravance Biopharma R&D Ip Llc | Naftiridino junginiai, kaip jak kinazės inhibitoriai |
| PT3712152T (pt) | 2015-11-03 | 2021-04-15 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase |
| WO2017077288A1 (en) | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| BR112018072168A2 (pt) | 2016-04-28 | 2019-02-12 | Theravance Biopharma R&D Ip, Llc | compostos derivados da pirimidina como inibidores da quinase jak |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| LT3555097T (lt) | 2016-12-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai |
| MD3672965T2 (ro) * | 2017-10-27 | 2022-12-31 | Theravance Biopharma R&D Ip Llc | Compusi ai pirimidinei ca inhibitori ai kinazei JAK |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| EP3810094A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| TWI740288B (zh) * | 2018-11-27 | 2021-09-21 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
| EP3889152A4 (en) * | 2018-11-30 | 2022-09-07 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATORS, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| TW202106681A (zh) | 2019-04-24 | 2021-02-16 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療皮膚疾病之嘧啶jak抑制劑 |
| JP7470713B2 (ja) | 2019-04-24 | 2024-04-18 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物 |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021238908A1 (zh) * | 2020-05-25 | 2021-12-02 | 上海翰森生物医药科技有限公司 | 杂芳类衍生物的盐、晶型及其制备方法 |
| TW202228689A (zh) | 2020-10-09 | 2022-08-01 | 美商賽若凡斯生物製藥研發智財有限責任公司 | 泛ｊａｋ抑制劑的調配物 |
| WO2022076714A1 (en) | 2020-10-09 | 2022-04-14 | Janssen Biotech, Inc. | Solid forms of a pan-jak inhibitor |
| WO2022076703A1 (en) | 2020-10-09 | 2022-04-14 | Janssen Biotech, Inc. | Processes for preparing a pan-jak inhibitor and related intermediate compounds |
| WO2022076717A1 (en) | 2020-10-09 | 2022-04-14 | Janssen Biotech, Inc. | Solvate forms of a pan-jak inhibitor |
| US20240158392A1 (en) * | 2021-02-01 | 2024-05-16 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| WO2022241188A1 (en) | 2021-05-14 | 2022-11-17 | Theravance Biopharma R&D Ip, Llc | Enantioselective synthesis of aminotropane compound |
| WO2023011359A1 (zh) * | 2021-08-05 | 2023-02-09 | 南京明德新药研发有限公司 | 桥环类化合物及其应用 |
| WO2023102800A1 (en) | 2021-12-09 | 2023-06-15 | Theravance Biopharma R&D Ip, Llc | Synthesis of 5, 7-dichloro-1, 6-naphthyridine |
| WO2023202706A1 (zh) * | 2022-04-21 | 2023-10-26 | 南京明德新药研发有限公司 | 硒杂环类化合物的盐型和晶型及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| IL156368A0 (en) | 2000-12-21 | 2004-01-04 | Vertex Pharma | Pyrazole derivatives and pharmaceutical compositions containing the same |
| EP1595881A1 (en) * | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| JP2008525422A (ja) * | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | 抗癌剤として有用な複素芳香族誘導体 |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| PE20090996A1 (es) * | 2007-04-02 | 2009-07-15 | Palau Pharma Sa | Derivados de pirrolopirimidina como inhibidores de cinasa jak3 |
| WO2010002472A1 (en) * | 2008-07-02 | 2010-01-07 | Ambit Biosciences Corporation | Jak kinase modulating compounds and methods of use thereof |
| WO2010015520A1 (de) * | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituierte naphthyridine und ihre verwendung als arzneimittel |
| BRPI0919488A2 (pt) | 2008-09-30 | 2015-12-01 | Astrazeneca Ab | composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| EP2527344A1 (en) * | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| CN105367555B (zh) | 2014-08-07 | 2019-06-25 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| LT3303348T (lt) | 2015-05-28 | 2019-11-25 | Theravance Biopharma R&D Ip Llc | Naftiridino junginiai, kaip jak kinazės inhibitoriai |
| BR112018072168A2 (pt) | 2016-04-28 | 2019-02-12 | Theravance Biopharma R&D Ip, Llc | compostos derivados da pirimidina como inibidores da quinase jak |
-
2016
- 2016-05-26 LT LT16728495T patent/LT3303348T/lt unknown
- 2016-05-26 MX MX2020011774A patent/MX2020011774A/es unknown
- 2016-05-26 EP EP19182836.7A patent/EP3569604B1/en active Active
- 2016-05-26 SI SI201630490T patent/SI3303348T1/sl unknown
- 2016-05-26 WO PCT/US2016/034243 patent/WO2016191524A1/en active Application Filing
- 2016-05-26 MX MX2017015211A patent/MX2017015211A/es unknown
- 2016-05-26 ES ES19182836T patent/ES2924698T3/es active Active
- 2016-05-26 JP JP2017561259A patent/JP6692836B2/ja active Active
- 2016-05-26 EP EP16728495.9A patent/EP3303348B1/en active Active
- 2016-05-26 CA CA2983453A patent/CA2983453A1/en not_active Abandoned
- 2016-05-26 HU HUE16728495A patent/HUE046130T2/hu unknown
- 2016-05-26 ES ES16728495T patent/ES2753159T3/es active Active
- 2016-05-26 KR KR1020177037794A patent/KR20180011272A/ko not_active Application Discontinuation
- 2016-05-26 RS RS20191390A patent/RS59522B1/sr unknown
- 2016-05-26 SG SG10201910742VA patent/SG10201910742VA/en unknown
- 2016-05-26 ME MEP-2019-289A patent/ME03610B/me unknown
- 2016-05-26 EA EA201792619A patent/EA032953B1/ru unknown
- 2016-05-26 CN CN201680029912.9A patent/CN107667108B/zh active Active
- 2016-05-26 US US15/165,126 patent/US9725470B2/en active Active
- 2016-05-26 BR BR112017025542-1A patent/BR112017025542A2/pt active Search and Examination
- 2016-05-26 PL PL16728495T patent/PL3303348T3/pl unknown
- 2016-05-26 UA UAA201712873A patent/UA121138C2/uk unknown
- 2016-05-26 DK DK16728495T patent/DK3303348T3/da active
- 2016-05-26 AU AU2016267141A patent/AU2016267141B2/en not_active Ceased
- 2016-05-26 CN CN202010325911.7A patent/CN111362975B/zh active Active
- 2016-05-26 PT PT167284959T patent/PT3303348T/pt unknown
- 2016-05-27 TW TW109132390A patent/TWI746178B/zh not_active IP Right Cessation
- 2016-05-27 TW TW105116751A patent/TWI704152B/zh not_active IP Right Cessation
-
2017
- 2017-06-23 US US15/631,220 patent/US10072026B2/en active Active
- 2017-10-27 ZA ZA2017/07326A patent/ZA201707326B/en unknown
- 2017-10-31 IL IL255358A patent/IL255358B/en active IP Right Grant
- 2017-11-09 PH PH12017502050A patent/PH12017502050A1/en unknown
- 2017-11-14 SA SA517390337A patent/SA517390337B1/ar unknown
- 2017-11-27 CL CL2017002994A patent/CL2017002994A1/es unknown
- 2017-11-29 CO CONC2017/0012267A patent/CO2017012267A2/es unknown
-
2018
- 2018-04-18 HK HK18105049.0A patent/HK1245771A1/zh unknown
- 2018-08-06 US US16/055,386 patent/US10494382B2/en active Active
-
2019
- 2019-10-11 US US16/599,434 patent/US10947254B2/en active Active
- 2019-11-06 CY CY20191101165T patent/CY1122279T1/el unknown
-
2020
- 2020-01-15 IL IL272057A patent/IL272057B/en active IP Right Grant
- 2020-03-19 JP JP2020049467A patent/JP6850922B2/ja active Active
- 2020-03-27 AU AU2020202181A patent/AU2020202181B2/en not_active Ceased
- 2020-08-12 IL IL276677A patent/IL276677B/en active IP Right Grant
- 2020-09-16 JP JP2020155460A patent/JP6942853B2/ja active Active
-
2021
- 2021-02-10 US US17/248,832 patent/US11780852B2/en active Active
- 2021-03-22 JP JP2021047526A patent/JP2021098757A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502050A1 (en) | Naphthyridine compounds as jak kinase inhibitors | |
| MX2018013191A (es) | Compuestos de pirimidina como inhibidores de la quinasa jak. | |
| PH12018500828A1 (en) | Jak kinase inhibitor compounds for treatment of respiratory disease | |
| PH12019501985A1 (en) | Fused imidazo-piperidine jak inhibitors | |
| PH12016501898A1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
| NZ729005A (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| MX2017006366A (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa. | |
| MX371312B (es) | Pirazolil-ureas como inhibidores de quinasas. | |
| PH12020500201A1 (en) | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors | |
| PH12015502248A1 (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| MX2016010106A (es) | Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| EA202192822A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
| PH12017501063A1 (en) | Compounds for the treatment of cancer | |
| MY192305A (en) | Bipyrazole derivatives as jak inhibitors |